Chinese Medical Journal article review decodes GDF15 in prostate cancer metabolic character and therapies
Peer-Reviewed Publication
Updates every hour. Last Updated: 6-Jun-2026 19:15 ET (6-Jun-2026 23:15 GMT/UTC)
This review provides a comprehensive analysis of Growth Differentiation Factor 15 (GDF15) in prostate cancer (PCa), examining its complex influence on tumor metabolism, chemoresistance, and bone metastasis. GDF15 is identified as a critical driver of PCa progression and cancer cachexia, offering diagnostic potential as a biomarker, especially when combined with PSA. The review highlights promising ongoing clinical trials involving monoclonal antibodies (e.g., AV-380, NGM120, Visugromab) that target GDF15 signaling, marking it as a significant therapeutic opportunity for novel PCa therapie
How comprehensive is our healthcare system, and who is being left behind? In this study, The University of Tokyo researchers synthesized the patients’ real-world experiences with complex genetic disorders into a single case. The study reveals how compartmentalized care leads to treatment refusal and patient harm, while coordinated interdisciplinary teams can restore well-being. It highlights the urgent need for reforms in medical education, care continuity, and health policy to create more inclusive, patient-centered healthcare systems.
Highlights
•
Genetic and epigenetic alterations, metabolic reprogramming, and survival mechanisms govern chemoresistance in cancer.
•
Cancer cells evade drug effects through metabolic reprogramming.
•
Resistance mechanisms are countered by tailored medicine and targeted medicines.
•
Combination regimens use a variety of strategies to overcome resistance
•
Novel treatment approaches to overcome resistance are guided by molecular understanding
Researchers have discovered that natural “sunscreen” compounds found in algae and cyanobacteria may also support skin and heart health. By comparing two mycosporine-like amino acids, the team showed for the first time that these molecules can block a key enzyme involved in blood pressure control in laboratory tests, while also offering antioxidant and anti-aging effects. The findings open new possibilities for cosmetics and functional foods based on nature-derived ingredients.
Emerging infectious diseases (EIDs), whether newly identified or re-emerging in human and animal populations, pose significant threats to global public health. China has experienced multiple EIDs outbreaks in recent years, underscoring the need for robust surveillance and early warning systems. Although China has established surveillance systems for events affecting climate, wildlife, livestock and poultry, and humans, the current systems remain inadequate for the early detection, monitoring, and prevention of zoonotic spillover events. The “One Health” approach, which integrates human, animal, and environmental health, offers a comprehensive strategy for mitigating EIDs risks. This study reviews China's national-level surveillance and early warning systems from a “One Health” perspective, highlighting key limitations and proposing future directions to enhance preparedness and response capabilities. The findings are intended to inform policy improvements and strengthen interdisciplinary collaboration for effective EIDs management.
The 2024 WHO Bacterial Priority Pathogens List (WHO BPPL) is a critical tool for refining global antimicrobial resistance (AMR) strategy, prioritizing 24 bacteria with a focus on Gram-negatives and community threats like Salmonella Typhi. This perspective examines its One Health implications. While the 2024 WHO BPPL effectively guides research and development (R&D), policy, and infection control through vaccines and water, sanitation and hygiene (WASH) programs, its human-centric approach underrepresents critical agricultural and environmental AMR drivers. Surveillance biases towards high-income countries and the inherent challenges of cross-sectoral monitoring—given the distinct niches of pathogens like Enterococcus faecium and Shigella—further limit its scope. We call for integrating zoonotic and environmental metrics, strengthening global surveillance (e.g., Global Antimicrobial Resistance and Use Surveillance System [GLASS]), and accelerating development of novel therapies to advance a more equitable and holistic AMR response.
New research by UCLA Health and UC San Francisco has uncovered why certain brain cells are more resilient than others to the buildup of a toxic protein that is a hallmark of Alzheimer’s disease and related dementias, potentially leading to new targets for therapies or treatments.